On the use of coenzyme therapeutic complex in patients with idiopathic Abramov-Fiedler myocarditis

Insufficient effectiveness of cardiotonic therapy in patients with Abramov-Fiedler myocarditis is largely due to profound metabolic changes in the affected heart muscle. These disturbances concern primarily the mechanisms of enzyme regulation of myocardial protein-synthetic and energy metabolism. The action of a number of coenzyme preparations synthesized in recent years is aimed at correction of these metabolic shifts. As a metabolic therapy we chose pyridoxalphosphate, a multifunctional biological agent that participates as a prosthetic group of transaminases, decarboxylases and other enzymes in reactions of synthesis of amino acids, purine and pyrimidine bases.